ImmunoGen Inc.
About ImmunoGen Inc.
ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology. The Company's lead product candidate, mirvetuximab soravtansine, is being advanced to Phase 3 testing for FRα-positive platinum-resistant ovarian cancer, and is also in Phase 1b/2 testing in combination regimens for earlier-stage disease. The Company's ADC technology is used in three other clinical-stage ImmunoGen product candidates, in Roche's marketed product, Kadcyla®, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda.
638 articles about ImmunoGen Inc.
-
After a slow start to 2023 in an uncertain economic climate, biopharma mergers and acquisitions are on the rise.
-
AbbVie Completes Acquisition of ImmunoGen
2/12/2024
AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of ImmunoGen (NASDAQ: IMGN).
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 01, 2024
2/1/2024
ImmunoGen, Inc. announced that the compensation committee of the Company’s Board of Directors approved, effective as of January 31, 2024, the grant of restricted stock units covering 68,940 shares of ImmunoGen’s common stock under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended to eleven new employees.
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 03, 2024
1/3/2024
ImmunoGen, Inc. announced that the compensation committee of the Company’s Board of Directors approved, effective as of December 29, 2023, the grant of restricted stock units covering 167,159 shares of ImmunoGen’s common stock under the ImmunoGen, Inc.
-
ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH
12/10/2023
ImmunoGen Inc. announced new safety and efficacy findings from the newly diagnosed cohorts of the Phase 1b/2 study of pivekimab sunirine in combination with azacitidine and venetoclax, in patients with ND acute myeloid leukemia.
-
FDA Grants Priority Review of ImmunoGen’s Supplemental Biologics License Application for ELAHERE® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer
12/5/2023
FDA Grants Priority Review of ImmunoGen’s Supplemental Biologics License Application for ELAHERE ® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer.
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 01, 2023
12/1/2023
ImmunoGen, Inc. announced that the compensation committee of the Company’s Board of Directors approved, effective as of November 30, 2023, the grant of restricted stock units covering 112,252 shares of ImmunoGen’s common stock under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended to twelve new employees.
-
AbbVie’s $10.1 billion ImmunoGen buy and Altimmune’s Phase II win demonstrate that the antibody-drug conjugate market is red hot in cancer and GLP-1 drugs for weight loss are an absolute craze.
-
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
11/30/2023
AbbVie Inc. (NYSE: ABBV) and ImmunoGen, Inc. (NASDAQ: IMGN) today announced a definitive agreement under which AbbVie will acquire ImmunoGen, and its flagship cancer therapy ELAHERE® (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC).
-
Facing the loss of Humira revenues from biosimilar competition, AbbVie is looking to grow its pipeline by acquiring ImmunoGen and its antibody-drug conjugate Elahere, which was granted FDA accelerated approval last year.
-
ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results
11/2/2023
ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2023.
-
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies London Healthcare Conference
11/2/2023
ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that the Company will participate in a fireside chat at the upcoming Jefferies London Healthcare Conference.
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 01, 2023
11/1/2023
ImmunoGen, Inc. announced that the compensation committee of the Company’s Board of Directors approved, effective as of October 31, 2023, grants of non-qualified stock options to purchase 2,650 shares of its common stock and restricted stock units covering 1,800 shares of its common stock under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended to a new employee.
-
ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
10/27/2023
ImmunoGen, Inc. announced that the European Medicines Agency has accepted the Marketing Authorization Application for mirvetuximab soravtansine for the treatment of patients with folate receptor alpha -positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
-
ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2023 Operating Results
10/19/2023
ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Thursday, November 2, 2023 to discuss its third quarter 2023 operating results.
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 29, 2023
9/29/2023
ImmunoGen, Inc. announced that the compensation committee of the Company’s Board of Directors approved, effective as of September 25, 2023, grants of non-qualified stock options to purchase 258,300 shares of its common stock and restricted stock units covering 43,050 shares of its common stock under the Inducement Plan to a new employee.
-
ELAHERE® Shows Overall and Progression-Free Survival Benefit Regardless of Prior PARPi Exposure or Prior Lines of Therapy in FRα-Positive Platinum-Resistant Ovarian Cancer
9/28/2023
ImmunoGen Inc. announced findings from two subset analyses of the Phase 3 confirmatory MIRASOL trial evaluating the safety and efficacy of ELAHERE® compared to chemotherapy in patients with folate receptor alpha -positive platinum-resistant ovarian cancer.
-
ImmunoGen Appoints Lauren White as Senior Vice President and Chief Financial Officer
9/18/2023
ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that Lauren White has been appointed Senior Vice President and Chief Financial Officer.
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 18, 2023
9/18/2023
ImmunoGen, Inc. announced that on September 18, 2023, and in connection with the previously announced appointment of Ms. Lauren White as ImmunoGen’s Senior Vice President and Chief Financial Officer, the compensation committee of the Company’s Board of Directors approved grants of non-qualified stock options to purchase 295,975 shares of its common stock and restricted stock units covering 51,625 shares of its common stock under the Inducement Plan to Ms. White.
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 05, 2023
9/5/2023
ImmunoGen, Inc. announced that the compensation committee of the Company’s Board of Directors approved, effective as of August 31, 2023, grants of non-qualified stock options to purchase an aggregate of 59,260 shares of its common stock and restricted stock units covering an aggregate of 29,630 shares of its common stock under the Inducement Plan to four new employees.